{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:41Z","timestamp":1790312441821,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03422-3","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:41:19Z","timestamp":1790311279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric\/GEJ adenocarcinoma"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"10389","key":"3422_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"3422_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"5","key":"3422_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21(5):354\u201369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3422_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"key":"3422_CR5","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.esmogo.2024.100131","volume":"7","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Pazo-Cid R, Lonardi S, et al. Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab plus chemotherapy: a RAND\/UCLA modified Delphi panel study. ESMO Gastrointest Oncol. 2025;7:100131. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100131.","journal-title":"ESMO Gastrointest Oncol"},{"key":"3422_CR6","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.esmogo.2024.100128","volume":"7","author":"K Shimozaki","year":"2025","unstructured":"Shimozaki K, Ooki A, Yamahata Y, et al. Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice. ESMO Gastrointest Oncol. 2025;7:100128. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100128.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"2","key":"3422_CR7","doi-asserted-by":"publisher","first-page":"105931","DOI":"10.1016\/j.esmoop.2025.105931","volume":"11","author":"K Shitara","year":"2026","unstructured":"Shitara K, Smyth E, Lordick F, et al. Impact and effective management of nausea\/vomiting on patients treated with zolbetuximab plus chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies. ESMO Open. 2026;11(2):105931. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105931.","journal-title":"ESMO Open"},{"key":"3422_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10120-026-01738-7","volume":"29","author":"K Yamaguchi","year":"2026","unstructured":"Yamaguchi K, Shoji H, Yasui H, et al. Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials. Gastric Cancer. 2026;29:777\u201387. https:\/\/doi.org\/10.1007\/s10120-026-01738-7.","journal-title":"Gastric Cancer"},{"key":"3422_CR9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s40262-025-01552-x","volume":"64","author":"J Yang","year":"2025","unstructured":"Yang J, Yamada A, Shitara K, et al. Clinical pharmacology profile of the claudin 18.2 antibody zolbetuximab. Clin Pharmacokinet. 2025;64:1465\u201376. https:\/\/doi.org\/10.1007\/s40262-025-01552-x.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3422_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jphs.2024.08.005","volume":"156","author":"F Kinugasa","year":"2024","unstructured":"Kinugasa F, Kajikawa S, Weng J, et al. Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. J Pharmacol Sci. 2024;156(3):161\u201370. https:\/\/doi.org\/10.1016\/j.jphs.2024.08.005.","journal-title":"J Pharmacol Sci"},{"issue":"10","key":"3422_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105805","volume":"10","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Owaki Y, Nakayama I, et al. Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ESMO Open. 2025;10(10):105805. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105805.","journal-title":"ESMO Open"},{"key":"3422_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40780-026-00569-z","volume":"12","author":"Y Ando","year":"2026","unstructured":"Ando Y, Banno H, Yamaguchi S, et al. Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study. J Pharm Health Care Sci. 2026;12:51. https:\/\/doi.org\/10.1186\/s40780-026-00569-z.","journal-title":"J Pharm Health Care Sci"},{"issue":"12","key":"3422_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121996","volume":"17","author":"Y Narita","year":"2025","unstructured":"Narita Y, Mizuno T, Suda T, et al. Practical management of zolbetuximab administration: the Project VYLOY initiative. Cancers (Basel). 2025;17(12):1996. https:\/\/doi.org\/10.3390\/cancers17121996.","journal-title":"Cancers (Basel)"},{"key":"3422_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-026-11024-y","volume":"34","author":"T Sagawa","year":"2026","unstructured":"Sagawa T, Umehara K, Izumi M, et al. Real-world implementation of a standardized administration protocol for zolbetuximab-associated nausea and vomiting: a retrospective supportive-care cohort study. Support Care Cancer. 2026;34:783. https:\/\/doi.org\/10.1007\/s00520-026-11024-y.","journal-title":"Support Care Cancer"},{"key":"3422_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00432-025-06406-4","volume":"152","author":"K Shimozaki","year":"2026","unstructured":"Shimozaki K, Ooki A, Fukuoka S, et al. Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience. J Cancer Res Clin Oncol. 2026;152:16. https:\/\/doi.org\/10.1007\/s00432-025-06406-4.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03422-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:41:34Z","timestamp":1790311294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03422-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3422"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03422-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"299"}}